Generate a tailored SOP for Dr. Jane Bayani. Improve your application with a focused, well-structured draft.
Jane Bayani is focused on precision medicine approaches to discover and validate biomarkers using large, well-annotated retrospective clinical trial cohorts. Her ongoing research investigates the impact of genomic, transcriptomic, and proteomic heterogeneity, integrating diagnostic testing modalities such as imaging and digital pathology to build a clinical toolbox aimed at improving risk assessment and treatment decision-making for cancers like breast and prostate. She has a significant interest in reducing overtreatment of patients by accelerating work in the liquid biopsy space and enhancing disease monitoring. Dr. Bayani has co-invented patented molecular signatures to aid in early diagnosis of hormone receptor-positive breast cancers and prostate cancer. She received her undergraduate degree from the University of Toronto and both her graduate degrees from the Department of Laboratory Medicine and Pathobiology, enhancing her extensive background in molecular pathology and cytogenetics.
Ontario Institute for Cancer Research • Toronto, Ontario, Canada
Co-Director for Diagnostic Development, leading research on precision medicine and diagnostic platforms.
Molecular signature for diagnosing early hormone receptor positive breast cancers.
Early prostate cancer risk signature for identifying occult high-grade cancer.
Department of Sociology